Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Antonio C. Wolff, M. Elizabeth Hammond, Daniel F. Hayes

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)957-958
Number of pages2
JournalJournal of the National Cancer Institute
Volume104
Issue number12
DOIs
StatePublished - Jun 20 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this